Clinical Trial Update: Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients

View source ↗

Summary

A completed clinical trial evaluated insulin glargine (Lantus) for beta-cell function support and cardiovascular protection in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)

Snippet

Sponsor: ikfe-CRO GmbH | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED